What is the recommended treatment for a 29-year-old male with a 7-year history of widespread hypopigmented lesions, mild erythema and scaling on dermoscopy, and no known comorbidities?

Treatment Recommendation for Widespread Hypopigmented Lesions with Mild Erythema and Scaling

Based on the clinical presentation of widespread hypopigmented lesions with mild erythema and scaling on dermoscopy in a 29-year-old male, the most likely diagnosis is vitiligo, and I recommend initiating treatment with narrowband UVB (NB-UVB) phototherapy three times weekly as first-line therapy, with consideration of adding a potent topical corticosteroid for a trial period of no more than 2 months. 1

Diagnostic Considerations

The clinical picture described—multiple hypopigmented lesions over the whole body including limbs, with mild erythema and minimal scaling on dermoscopy—is most consistent with vitiligo. However, the presence of scaling raises important differential diagnoses that must be excluded:

• Pityriasis versicolor: The scaling component makes this a key differential. A simple Scotch tape test or KOH preparation should be performed to exclude fungal elements 2
• Hypopigmented mycosis fungoides (HMF): Though rare in this age group, the chronic 7-year history and scaling warrant consideration, particularly if lesions show anhidrosis or unusual distribution 3, 4
• Pityriasis alba: More common in children but can occur in young adults

Critical pitfall: Do not assume vitiligo without excluding pityriasis versicolor, especially given the dermoscopic finding of scaling. A negative fungal examination is essential before committing to long-term phototherapy.

Treatment Algorithm for Confirmed Vitiligo

First-Line Therapy: Phototherapy

NB-UVB phototherapy is the preferred treatment for widespread vitiligo based on superior efficacy and safety compared to PUVA 1. The treatment protocol:

• Frequency: Three times weekly
• Safety limit: Maximum 200 treatments for skin types I-III (evidence lacking for upper limits in darker skin types IV-VI) 1
• Monitoring: Serial photographs every 2-3 months to document response 1

The guideline explicitly states that "if phototherapy is to be used for treating nonsegmental vitiligo, NB-UVB should be used in preference to PUVA in view of evidence of greater efficacy, safety" 1.

Adjunctive Topical Therapy

For recent-onset vitiligo, add a potent or very potent topical corticosteroid for a trial period of no more than 2 months 1. This recommendation comes with important caveats:

• Benefits have been observed in repigmentation
• Skin atrophy is a common side-effect, limiting duration of use
• Response rates are modest: only 10 of 23 subjects showed 15-25% repigmentation in key studies 1

Alternative topical option: Topical pimecrolimus can be considered as an alternative to topical steroids, with a better side-effect profile than highly potent topical steroids, though evidence is limited to one study 1.

Treatment Considerations Based on Patient Factors

For this 29-year-old male with no comorbidities:

• Skin type matters: If he has darker skin (types IV-VI), phototherapy may be particularly beneficial, though safety limits are not well-defined 1
• Extent of involvement: With whole body involvement including limbs, systemic phototherapy is more practical than topical treatments alone
• Duration of disease: The 7-year history suggests this is established vitiligo, making spontaneous repigmentation unlikely without intervention

What NOT to Do

Avoid oral dexamethasone: The guideline explicitly states that "the use of oral dexamethasone to arrest progression of vitiligo cannot be recommended due to an unacceptable risk of side-effects" 1

Surgical treatments are not appropriate at this stage, as they are reserved for:

• Cosmetically sensitive sites
• Patients with no new lesions for 12 months
• No Koebner phenomenon
• No extension of lesions 1

Depigmentation Therapy

This patient is NOT a candidate for depigmentation therapy, which should be reserved only for patients with:

• More than 50% depigmentation, OR
• Extensive depigmentation on face or hands when repigmentation attempts have failed
• Acceptance of permanent inability to tan 1

Monitoring and Follow-Up

• Serial photographs: Essential for objective monitoring of treatment response 1
• Quality of life assessment: Vitiligo significantly impacts QOL, particularly in darker-skinned individuals 1
• Psychological support: Should be offered as vitiligo can have substantial psychosocial impact 1

If Initial Diagnosis is Uncertain

Given the dermoscopic finding of scaling, if fungal examination is positive, the diagnosis shifts to pityriasis versicolor, which requires:

• Oral fluconazole for rapid resolution 2
• Complete change in management approach

If histopathology reveals Pautrier microabscesses or atypical lymphocytes, the diagnosis becomes hypopigmented mycosis fungoides, requiring:

• Skin-directed therapy as first-line 4
• Consideration of interferon-alpha for more effective response 5
• Long-term follow-up due to potential for progression 4

The key is to confirm the diagnosis before committing to months of phototherapy—perform fungal studies first, and consider biopsy if clinical response to initial vitiligo treatment is poor or if atypical features develop.